Increased risk of portal vein thrombosis in patients with autoimmune hepatitis on the liver transplantation waiting list

Ruíz, Pablo; Sastre, Lydia; Crespo, Gonzalo; Blasi, Annabel; Colmenero, Jordi; García‐Valdecasas, Juan Carlos; Navasa, Miquel

doi:10.1111/ctr.13001

Cited by 9 publications

(3 citation statements)

References 27 publications

(29 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There has been only a handful of studies investigating the crosstalk between biliary cirrhosis and PVT/portal spongiform. One study [ 30 ] reported an increased risk of PVT in the patients with autoimmune hepatitis awaiting liver transplantation, which is inconsistent with the findings of the present study. Regarding the underlying etiologies, the low risk of PVT and/or cavernous changes in the patients with biliary cirrhosis has been linked to the medications taken by this group of patients.…”

Section: Discussioncontrasting

confidence: 99%

Analysis of Complications and Risk Factors Other than Bleeding before and after Endoscopic Treatment of Esophagogastric Variceal Bleeding in Patients with Liver Cirrhosis

Duan

He²,

Yan³

et al. 2023

Canadian Journal of Gastroenterology and Hepatology

View full text Add to dashboard Cite

Objective. To identify any concomitant complications other than bleeding (COTB) before and after endoscopic treatment of esophagogastric variceal bleeding (EGVB) in liver cirrhosis patients and explore the underlying risk factors. Materials and Methods. Cirrhotic patients complicated with EGVB, who underwent interventional endoscopic treatments in our hospital from November 2017 to August 2020, were enrolled in this study. Clinical data were retrospectively analyzed for COTB at admission and within 2 years of the first endoscopic treatment. Patients were screened for potential risk factors of COTB before and after the treatment. Univariate analysis was performed to identify clinical factors of secondary complications, and statistically significant factors were included in the multivariate Cox and logistic regression analyses. Results. Of the 547 patients with cirrhosis, 361 individuals had COTB in the first endoscopic treatment. In this cohort, the top 3 prevalent incidences were portal vein thrombosis (PVT) or spongiosis, cholelithiasis, and pathogenic infections. The COTB did not occur at admission in 171 liver cirrhosis patients but happened at the follow-up. Higher Child-Pugh scores indicated potential risks of multiple concurrent complications, including bleeding. Risk factors for concomitant PVT or cavernous changes after endoscopic treatment of EGVB, pathogenic infections, and cholelithiasis could prolong the cirrhosis symptoms, while noncholestatic cirrhosis patients might have a lower risk than posthepatitis B cirrhosis patients, in the context of a higher degree of EGV and serum level of D-D and a lower blood calcium level. Conclusions. Clinical treatment and interventions can be tailored to avoid other complications during and after EGVB treatment, which can affect the outcome and prognosis of bleeding symptoms.

show abstract

Section: Discussioncontrasting

confidence: 99%

Analysis of Complications and Risk Factors Other than Bleeding before and after Endoscopic Treatment of Esophagogastric Variceal Bleeding in Patients with Liver Cirrhosis

Duan

He²,

Yan³

et al. 2023

Canadian Journal of Gastroenterology and Hepatology

View full text Add to dashboard Cite

show abstract

“…Other factors previously suggested as potential risk factors for PVT such as obesity, 45 large esophageal varices, previous variceal endoscopic treatment 8,13,14 or etiology of liver disease, especially metabolic dysfunction-associated fatty liver disease (MAFLD) 8,13,46,47 were not confirmed in our prospective study. However, only 13 patients in our cohort had MAFLD, so no firm conclusions can be drawn.…”

Section: Discussioncontrasting

confidence: 73%

Predicting portal thrombosis in cirrhosis: A prospective study of clinical, ultrasonographic and hemostatic factors

Turón

Driever

Baiges

et al. 2021

Journal of Hepatology

Self Cite

101

109

View full text Add to dashboard Cite

“…Whereas another study shows that MASH patients have a lower risk of venous thromboembolism (VTE) [20]. Similarly, an observational study from Europe showed that among transplant-listed patients, PVT frequency was higher in nonmetabolic dysfunction-associated steatotic liver disease (MASLD) etiologies (autoimmune liver disease followed, cryptogenic, alcohol liver disease and viral liver disease) [21]. One European study had shown that chronic hepatitis C infection even without cirrhosis was associated with a higher pro-coagulant balance [22].…”

Section: Introductionmentioning

confidence: 99%

Metabolic dysfunction-associated steatotic liver disease related cirrhosis and incidence of portal vein thrombosis

Amjad,

Jiang,

Lai

2024

European Journal of Gastroenterology &Amp; Hepatology

View full text Add to dashboard Cite

Background There is heterogeneous data on whether metabolic-associated steatohepatitis is an independent risk factor for portal vein thrombosis (PVT). We aim to compare the incidence of PVT in patients with cirrhosis with and without metabolic dysfunction-associated steatotic liver disease (MASLD). Methods This is a single-center retrospective study of patients with cirrhosis seen between 1 January 2016 and 31 January 2021. Patients with a history of hepatocellular cancer, liver transplant, Budd-Chiari syndrome, and intra-abdominal malignancies were excluded. Patients with cirrhosis were followed from their first hepatology visit for 180 days to determine the incidence of PVT. Cox proportional hazard regression was used to determine the relationship between MASLD with PVT. Results We analyzed data from 2785 patients with cirrhosis who met inclusion and exclusion criteria [mean age: 61.0 ± 12.3 years, 44.3% female, 63.8% Whites and mean model for end-stage liver disease-sodium (MELD-Na) score: 11.7 ± 6.1]. MASLD was present in 21.7% of patients. A total of 89 patients developed PVT during the follow-up, which was fewer in patients with MASLD [2.0% vs. 3.5%, P = 0.04, unadjusted heart rate (HR): 0.60, 95% confidence interval (CI): 0.27–0.96, P = 0.04]. After adjusting for the demographics, MASLD-related comorbid conditions and MELD-Na score, MASLD was associated with a lower incidence of PVT as compared to non-MASLD cirrhosis (HR: 0.44, 95% CI: 0.21–0.92, P = 0.03). After adjusting for the indicators of Child-Pugh Turcotte score, the risk of PVT in patients with MASLD compared to non-MASLD was not statistically significant (HR: 0.50, 95% CI: 0.22–1.13, P = 0.096). Conclusion PVT incidence was lower in patients with MASLD cirrhosis as compared to non-MASLD cirrhosis. However, the difference was not significantly different after adjusting for liver decompensation.

show abstract

Increased risk of portal vein thrombosis in patients with autoimmune hepatitis on the liver transplantation waiting list

Cited by 9 publications

References 27 publications

Analysis of Complications and Risk Factors Other than Bleeding before and after Endoscopic Treatment of Esophagogastric Variceal Bleeding in Patients with Liver Cirrhosis

Analysis of Complications and Risk Factors Other than Bleeding before and after Endoscopic Treatment of Esophagogastric Variceal Bleeding in Patients with Liver Cirrhosis

Predicting portal thrombosis in cirrhosis: A prospective study of clinical, ultrasonographic and hemostatic factors

Metabolic dysfunction-associated steatotic liver disease related cirrhosis and incidence of portal vein thrombosis

Contact Info

Product

Resources

About